Other News

BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart

GOLD COAST, Australia & HUNTINGTON BEACH, Calif.–(BUSINESS WIRE)–BiVACOR®, a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements. Led by Monash […]

Cagent Vascular Raises $30 Million Series C Financing

WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, today announced a Series C Financing close in excess of $30M. U.S. Venture Partners (USVP), led the round. Participation included new investor Blue Ridge Medical, LLC and existing investors, including Sectoral Asset Management. “We are pleased with […]

Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis

BERLIN–(BUSINESS WIRE)–Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT). The results of this study might provide evidence of anti-α2ap antibody’s potential as a treatment option in indications of high […]

Endovascular Engineering Announces First Patient Enrolled in ENGULF Pivotal Trial with its Hēlo™ PE Thrombectomy System for the Treatment of Pulmonary Embolism

MENLO PARK, Calif., Feb. 20, 2024 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”), a pioneering medical device company at the forefront of advancing clot removal technologies for venous thromboembolism (VTE), proudly announces the enrollment and treatment of the first patient in the…

BioSig Announces Reduction of its Workforce

Westport, CT, Feb. 20, 2024 (GLOBE NEWSWIRE) — — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company, today announced that it has terminated a significant number of its employees and expects to substantially reduce business operations. About BioSig Technologies, Inc. BioSig Technologies is a medical […]

Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

ST. LOUIS, Feb. 20, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 fourth quarter and full year ended December 31, 2023 on Monday, March 4, 2024 at […]

GE HealthCare Technologies Inc. Prices Secondary Offering of 13,000,000 Shares

CHICAGO–(BUSINESS WIRE)–Feb. 16, 2024– GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $82.25 per share ($80.605 per share, net of underwriting discount). GE […]

Butterfly Network, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

BURLINGTON, Mass. & NEW YORK–(BUSINESS WIRE)–Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the market closes. Joseph DeVivo, President, Chief Executive Officer […]